New launches take center stage as Biogen Idec outsources R&D
This article was originally published in Scrip
Executive Summary
As Biogen Idec gears up for major launch activities with promising new compounds Tecfidera for multiple sclerosis and Alprolix for hemophilia B, it is ensuring that its clinical development pipeline gets the attention it deserves through a new five-year tie-up with contract research organization Quintiles.